InterventionsResearch
MON-701 A case which GLP 1 receptor agonist semaglutide enabled the management of both obesity and diabetes mellitus, suggesting the potential for diabetes remission
ENDO 2025 Abstract
Related
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Nature Medicine · 4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026